Pulmonary embolism

Last updated: July 13, 2026

Pulmonary embolism

Watch later

Watch later

Multiple endocrine neoplasia
Seronegative and septic arthritis: Pathology review
Primary sclerosing cholangitis
Papulosquamous and inflammatory skin disorders: Pathology review
Bleeding disorders: Clinical
Nephritic and nephrotic syndromes: Clinical
Nephrotic syndromes: Pathology review
Nephritic syndromes: Pathology review
Aortic dissections and aneurysms: Pathology review
Reactive arthritis
Seronegative arthritis: Clinical
Chronic obstructive pulmonary disease (COPD): Clinical
Rheumatoid arthritis: Clinical
Systemic lupus erythematosus (SLE): Pathology review
MEN syndromes: Clinical
Leg ulcers: Clinical
Breast cancer: Pathology review
Parkinson disease
Non-Hodgkin lymphoma
Lymphomas: Pathology review
Lymphoma: Clinical
Cushing syndrome
Cushing syndrome: Clinical
Cushing syndrome and Cushing disease: Pathology review
Cirrhosis: Clinical
Physiological changes during exercise
Role of Vitamin K in coagulation
Clot retraction and fibrinolysis
Thrombotic thrombocytopenic purpura
Thrombocytopenia: Clinical
Hemophilia
Coagulation disorders: Pathology review
Chronic leukemia
Anemia of chronic disease
Peripheral artery disease: Pathology review
Peripheral vascular disease: Clinical
Dermatomyositis
Myalgias and myositis: Pathology review
Hypocalcemia
Hypercalcemia
Hypokalemia
Hypernatremia
Hypernatremia: Clinical
Hyponatremia: Clinical
Hypokalemia: Clinical
Hypomagnesemia
Miscellaneous hypoglycemics
Insulins
Renal artery stenosis
Antiplatelet medications
Macrocytic anemia: Pathology review
Microcytic anemia: Pathology review
Acneiform skin disorders: Pathology review
Staphylococcus aureus
Streptococcus pyogenes (Group A Strep)
Herpes simplex virus
Chronic kidney disease
Vitamin B12 deficiency
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Goodpasture syndrome
Myelodysplastic syndromes
Sjogren syndrome
Sjogren syndrome: Pathology review
Sjogren syndrome: Clinical
Psoriasis
Crohn disease
Acute pyelonephritis
Chronic pyelonephritis
Hypoglycemics: Insulin secretagogues
Gout
Gout and pseudogout: Pathology review
Ulcerative colitis
Inflammatory bowel disease: Clinical
Celiac disease
DNA alkylating medications
Chronic kidney disease: Clinical
Hidradenitis suppurativa
ACE inhibitors, ARBs and direct renin inhibitors
Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
Bone tumors
Pediatric bone tumors: Clinical
Bone tumors: Pathology review
Developmental dysplasia of the hip
Venous thromboembolism: Clinical
Carpal tunnel syndrome
Heart failure
Thiazide and thiazide-like diuretics
Calcium channel blockers
Adrenergic antagonists: Beta blockers
Positive inotropic medications
Hyperthyroidism
Hyperthyroidism: Pathology review
Lichen planus
Viral hepatitis: Clinical
Hepatitis medications
Viral hepatitis: Pathology review
Autoimmune hepatitis
Pleural effusion: Clinical
Hyperthyroidism medications
Hypothyroidism medications
Rotator cuff tear
Anatomy clinical correlates: Clavicle and shoulder
Breast cancer: Clinical
Osteomalacia and rickets
Pelvic inflammatory disease
Mastocytosis (NORD)
Hernias: Clinical
Abdominal hernias
von Hippel-Lindau disease
PDE5 inhibitors
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Pemphigus vulgaris
Polycystic ovary syndrome
Miscellaneous lipid-lowering medications
Monoclonal antibodies
Osteoarthritis
Rheumatoid arthritis and osteoarthritis: Pathology review
Cytokines
Glucocorticoids
Platelet plug formation (primary hemostasis)
Coagulation (secondary hemostasis)
Platelet disorders: Pathology review
Deep vein thrombosis
Pulmonary embolism
Thrombophlebitis
Opioid agonists, mixed agonist-antagonists and partial agonists
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Opioid antagonists
Anticoagulants: Heparin
Heparin-induced thrombocytopenia
Peripheral artery disease
Focal segmental glomerulosclerosis (NORD)
Minimal change disease
Membranous nephropathy
Poststreptococcal glomerulonephritis
IgA nephropathy (NORD)
Membranoproliferative glomerulonephritis
Rapidly progressive glomerulonephritis
Anticonvulsants and anxiolytics: Benzodiazepines
Diverticulosis and diverticulitis
Sarcoidosis
Acute leukemia
Vasculitis
Primary biliary cholangitis
Hyperkalemia
Jaundice
Stevens-Johnson syndrome
Osteoporosis medications
General anesthetics
Selective serotonin reuptake inhibitors
Systemic lupus erythematosus (SLE): Clinical
Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Diabetes insipidus and SIADH: Pathology review
Hepatic encephalopathy
Osteomyelitis
Fibromyalgia
Cell-mediated immunity of natural killer and CD8 cells
Ankylosing spondylitis
Septic arthritis
Hyperparathyroidism
Parathyroid conditions and calcium imbalance: Clinical
Heart failure: Clinical
Cardiomyopathies: Pathology review
Cardiomyopathies: Clinical
Gastrointestinal bleeding: Pathology review
Acute pancreatitis
Pancreatitis: Clinical
Pancreatitis: Pathology review
GERD, peptic ulcers, gastritis, and stomach cancer: Pathology review
Gastroesophageal reflux disease (GERD)
Peptic ulcers and stomach cancer: Clinical
Gastric cancer
Colorectal polyps
Colorectal cancer
Colorectal polyps and cancer: Pathology review
Colorectal cancer: Clinical
Respiratory distress syndrome: Pathology review
Acute respiratory distress syndrome: Clinical
Pediatric infectious rashes: Clinical
Parathyroid disorders and calcium imbalance: Pathology review
Phosphate, calcium and magnesium homeostasis
Obstructive lung diseases: Pathology review
Fever of unknown origin: Clinical
Malabsorption: Clinical
Neurocutaneous disorders: Pathology review
Diabetes mellitus
Diabetes mellitus: Pathology review
Diabetes mellitus: Clinical
Acute kidney injury: Clinical
Neisseria gonorrhoeae
Non-urothelial bladder cancers
Alopecia: Clinical
Esophageal disorders: Clinical
Esophageal disorders: Pathology review
Esophageal surgical conditions: Clinical
Peptic ulcer
Porphyria cutanea tarda
Acute intermittent porphyria
Myocardial infarction
Hypopigmentation skin disorders: Clinical
Subdural hematoma
Alport syndrome
Bullous pemphigoid
Thyroid nodules and thyroid cancer: Clinical
Pheochromocytoma
Kidney stones: Clinical
Asthma: Clinical
Pneumonia: Pathology review
Pneumonia: Clinical
Diarrhea: Clinical
Jaundice: Pathology review
Restrictive lung diseases: Pathology review
Renal failure: Pathology review

Transcript

Watch video only

A pulmonary embolism happens when an embolus, which is a type of blockage, suddenly gets lodged inside a pulmonary artery.

Depending on which pulmonary artery or arteries are affected by the blockage, that can seriously decrease the amount of oxygenated blood that gets out to the body.

Normally, blood makes it back to the heart from all of the tissues and organs through a network of veins that merge over and over.

Superficial veins drain blood into deep veins, which rely on the skeletal muscle pump to move blood forward. The way it works is that the surrounding skeletal muscles compress the vein and propel blood forward, and the veins prevent blood from moving backwards by using one-way valves.

Ultimately, all of the blood ends up in the superior or inferior vena cava and dumps into the right atrium.

From there the blood goes into the right ventricle and gets pumped into pulmonary artery and eventually into the lungs.

The pulmonary artery splits at a spot called the pulmonary saddle, which looks like a bit like a horse saddle, and then the right and left pulmonary arteries enter their respective lungs.

Subsequent branches off the pulmonary artery lead to smaller and smaller arteries, then arterioles, and finally capillaries that form nets around the alveoli, which is where gas exchange occurs.

When a pulmonary embolism happens, a blockage in any of the arteries leads to a decrease in blood flow to lung tissue downstream.

The majority of the time, this blockage is caused by a broken off piece of a blood clot commonly associated with deep vein thrombosis.

A deep vein thrombosis most commonly develops in the lower legs, below the knee, although a blood clot can form in both superficial and deep veins and also in other parts of the body as well.

Normally, the process starts with damage to the endothelium, or inner lining of blood vessel walls, after which there’s an immediate vasoconstriction or narrowing of the blood vessel which limits the amount of blood flow.

After that, some platelets adhere to the damaged vessel wall, and become activated by collagen and tissue factor, which are proteins that are normally kept separated from the blood by an intact endothelium.

These platelets then recruit additional platelets to form a platelet plug. This formation of the platelet plug is called primary hemostasis.

After that, the coagulation cascade is activated.

First off in the blood there’s a set of clotting factors, most of which are proteins synthesized by the liver, and usually these are inactive and just floating around in the blood.

The coagulation cascade starts when one of these proteins gets proteolytically cleaved.

This active protein then proteolytically cleaves and activates the next clotting factor, and so on.

The final step is activation of the protein fibrinogen to fibrin, which deposits and polymerizes to form a mesh around the platelets.

So these steps leading up to fibrin reinforcement of the platelet plug make up the process called secondary hemostasis and results in a hard clot at the site of the injury.

This cascade has a huge degree of amplification and takes only a few minutes from injury to clot formation.

So the activation of the cascade is carefully controlled by anticoagulation proteins that target and inactivate key clotting factors.

For example, antithrombin inactivates Factors IXa, Xa, XIa, XIIa, VIIa and thrombin while protein C inactivates Factors Va and VIIIa.

As the clot grows in size, it limits the amount of blood able to pass by, and pressure in the vein increases.

Usually the clot might start naturally breaking down, for example, enzymes like plasmin break down fibrin into fragments called D-dimers.

But sometimes, the increased pressure in the vein can cause a part of the main clot to break free, becoming a thromboembolus which can travel downstream towards the heart.

When that happens, a thromboemobolus - which is a blood clot on the move - can move from the spot of clot formation and get into the right atrium, and then into the right ventricle and get pumped into the lungs where it can get lodged some place - causing a pulmonary thromboembolism. This is a life-threatening situation because it literally blocks blood from getting into the lungs to pick up oxygen.

If there’s no blood flowing past an alveoli, then that means there are alveoli that are getting ventilated with fresh air but not getting perfused with blood. We call this a ventilation perfusion mismatch or a V/Q mismatch.

The body needs oxygenated blood to function and can therefore only tolerate a bit of a V/Q mismatch, before the lungs are no longer able to meet the needs of the body.

The amount of V/Q mismatch ultimately depends on the number, size, and location of the pulmonary thromboembolisms, which tells us the amount of lung tissue that’s being denied blood flow.

A physiologic response to all of this is hyperventilation.

Key Takeaways

Pulmonary embolism (PE) is a blockage of the lungs main artery or one of its branches by a substance that has traveled from elsewhere in the body through the bloodstream (embolism). PE most commonly results from a deep vein thrombosis (commonly a blood clot in a leg) that breaks off and migrates to the lung, a process termed venous thromboembolism (VTE). This can cause serious damage to the lung tissue and can be life-threatening.

Symptoms vary by the amount of downstream lung tissue denied blood, which creates a ventilation-perfusion mismatch. They include shortness of breath, chest pain, and coughing. PE can also cause low blood oxygen levels, which can lead to confusion, loss of consciousness, and even death. Treatment of PE typically involves supportive therapy and blood thinning medications to dissolve the clot and prevent further clots from forming. Sometimes a filter is placed in the vena cava to trap clots before they reach the lungs.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  5. "Thrombosis" Arteriosclerosis, Thrombosis, and Vascular Biology (2014)
  6. "Acute pulmonary embolism: An update on diagnosis and management" Current Problems in Cardiology (2005)
  7. "Epidemiology, Pathophysiology, and Natural History of Pulmonary Embolism" Seminars in Interventional Radiology (2018)